Diagnostic anti-Canine adenovirus type 2 (CAV-2,CAV-Ⅱ) antibodies pairs and antigens for animal health (animal infectious disease ) testing in ELISA test,competitive ELISA test, blocking ELISA test, Lateral flow immunoassay (LFIA), colloidal gold immunochromatographic assay, Chemiluminescent immunoassay (CLIA), turbidimetric inhibition immuno assay (TINIA), and immunonephelometry
Catalog Number: GMP-AD-Pet-4
Definition of the disease: Canine adenovirus type 2 (CAV-2) is related to the hepatitis virus, canine adenovirus type 1 (CAV-1). CAV-2 is used in vaccines to provide protection against canine infectious hepatitis. CAV-2 is also one of the causes of infectious tracheobronchitis, also known as canine cough.
Genemedi produces core animal health diagnostic ingredients-validated antibodies pairs Mouse anti-Canine adenovirus type 2 (CAV-2,CAV-Ⅱ) monoclonal antibodies and Canine adenovirus type 2 (CAV-2,CAV-Ⅱ) antigens for rapid test kit of animal infectious disease with Canine adenovirus type 2 (CAV-2,CAV-Ⅱ) to evaluate the animal health of Pet.
The paired antibodies are both monoclonal antibody(mab).
All the antibodies and antiges of animal disease test are suitable for in functional ELISA, and other immunoassays in dignostics.The antibody can act as a capture antibody and detection antibody. Antigens are validated as positive control materials.
Order information
Catalog No. (1~4, 4 antibodies in pairs) |
Size | Price(In USD) | Qty (Quantity) | Sum(In USD) |
---|---|---|---|---|
GMP-AD-Pet-4Ab-1 | Size:1mg | 3090 | ||
GMP-AD-Pet-4Ab-1 | Size:10mg | 21935 | ||
GMP-AD-Pet-4Ab-1 | Size:100mg | 148000 | ||
GMP-AD-Pet-4Ab-2 | Size:1mg | 3090 | ||
GMP-AD-Pet-4Ab-2 | Size:10mg | 21935 | ||
GMP-AD-Pet-4Ab-2 | Size:100mg | 148000 | ||
GMP-AD-Pet-4Ab-3 | Size:1mg | 3090 | ||
GMP-AD-Pet-4Ab-3 | Size:10mg | 21935 | ||
GMP-AD-Pet-4Ab-3 | Size:100mg | 148000 | ||
GMP-AD-Pet-4Ab-4 | Size:1mg | 3090 | ||
GMP-AD-Pet-4Ab-4 | Size:10mg | 21935 | ||
GMP-AD-Pet-4Ab-4 | Size:100mg | 148000 | ||
GMP-AD-Pet-4Ag-1 | Size:1mg | 3090 | ||
GMP-AD-Pet-4Ag-1 | Size:10mg | 21935 | ||
GMP-AD-Pet-4Ag-1 | Size:100mg | 148000 | ||
GMP-AD-Pet-4Ag-2 | Size:1mg | 3090 | ||
GMP-AD-Pet-4Ag-2 | Size:10mg | 21935 | ||
GMP-AD-Pet-4Ag-2 | Size:100mg | 148000 | ||
Shipping Cost: | 760.00 | |||
Total: | ||||
Description
GMP-AD-Pet-4Ab, GMP-AD-Pet-4Ag
Cat No. | GMP-AD-Pet-4Ab |
Antigens | Canine adenovirus type 2 (CAV-2,CAV-Ⅱ) |
Antibody | Mouse anti-Canine adenovirus type 2 (CAV-2,CAV-Ⅱ) monoclonal antibodies |
Resource (expression host) | hybridoma |
Specics/Isotypes | Mouse IgG |
Bioactivity validation | Antibody Binding, Immunogen in Sandwich Elisa, lateral-flow tests,and other immunoassays in Canine adenovirus type 2 (CAV-2,CAV-Ⅱ) level test and Pet-diagnositcs. |
Antigen description | A candidate vaccine virus (CVV) is an influenza (flu) virus that has been prepared by CDC or another public health partner that can be used by vaccine manufacturers to produce a flu vaccine. In addition to preparing CVVs for seasonal flu vaccine production, CDC routinely develops CVVs for novel avian influenza (bird flu) viruses with pandemic potential as part of pandemic preparedness activities. Some novel bird flu viruses with pandemic potential are “highly pathogenic avian influenza” (HPAI) viruses, which means they are deadly to domestic poultry, including chickens. Data collected through global and animal flu surveillance informs the selection of CVVs, and experts choose CVVs against bird flu viruses in nature (“wild type” viruses) that pose a risk to human health. |
Purity | Purity: ≥95% (SDS-PAGE) |
Application | Paired antibody immunoassay validation in Sandwich ELISA, Lateral flow immunoassay (LFIA), and other immunoassays; |
Formulation | Lyophilized from sterile PBS, PH 7.4 |
Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Cat No. | GMP-AD-Pet-4Ag |
Antigens | Canine adenovirus type 2 (CAV-2,CAV-Ⅱ) |
Resource (expression host) | E.coli |
Specics/Isotypes | Canine adenovirus type 2 (CAV-2,CAV-Ⅱ) |
Bioactivity validation | Antibody Binding, Immunogen in Sandwich Elisa, lateral-flow tests,and other immunoassays in Canine adenovirus type 2 (CAV-2,CAV-Ⅱ) level test and Pet-diagnositcs. |
Tag | His |
Antigen description | A candidate vaccine virus (CVV) is an influenza (flu) virus that has been prepared by CDC or another public health partner that can be used by vaccine manufacturers to produce a flu vaccine. In addition to preparing CVVs for seasonal flu vaccine production, CDC routinely develops CVVs for novel avian influenza (bird flu) viruses with pandemic potential as part of pandemic preparedness activities. Some novel bird flu viruses with pandemic potential are “highly pathogenic avian influenza” (HPAI) viruses, which means they are deadly to domestic poultry, including chickens. Data collected through global and animal flu surveillance informs the selection of CVVs, and experts choose CVVs against bird flu viruses in nature (“wild type” viruses) that pose a risk to human health. |
Purity | Purity: ≥95% (SDS-PAGE) |
Application | Paired antibody immunoassay validation in Sandwich ELISA, Lateral flow immunoassay (LFIA), and other immunoassays; |
Formulation | Lyophilized from sterile PBS, PH 7.4 |
Storage | Store at -20℃ to -105℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
- GENEMEDI
- Email: [email protected] [email protected]
- Telephone: +86-21-50478399 Fax: 86-21-50478399
- Privacy Policy
- TECHNICAL SUPPORT
- Product FAQs
- Technical manuals
- Publications
- Email: [email protected]